Fig. 2
From: Glypican 3 as target therapy to prevent cell migration and proliferation in rhabdomyosarcoma
GPC3 expression over time and adhesion assay and cell migration. (A). GPC3 expression at different time points following a second siRNA treatment. The GPC3 expression in siRNA-treated cells was consistently lower compared to wild-type (WT) cells, even after 96 h of treatment. (B). Adhesion assay analysis reveal that WT cells exhibit superior adhesion compared to siRNA-treated cells in the presence of a fibronectin (FN) coating. (C). Gross appearance of the cells in the migration assay of WT and siRNA treated cells. Scale bar 75 μm. Quantification of the migrated cells. Treated cells did not migrate through the transwell like WT cell. (D). Gross appearance of the cells in the wound healing assay with WT cells and with siRNA treated cells. WT cells closed the wound while siRNA treated cells did not, in particular the ARMS cell line RH30. (E). Quantification of the wound healing assay. (Mann-Whitney test; **: p < 0.01; ***: p < 0.001). N = 4 experiments. In each experiment 4 replicates per each condition.
